JP2022525193A5 - - Google Patents

Info

Publication number
JP2022525193A5
JP2022525193A5 JP2021555433A JP2021555433A JP2022525193A5 JP 2022525193 A5 JP2022525193 A5 JP 2022525193A5 JP 2021555433 A JP2021555433 A JP 2021555433A JP 2021555433 A JP2021555433 A JP 2021555433A JP 2022525193 A5 JP2022525193 A5 JP 2022525193A5
Authority
JP
Japan
Prior art keywords
nucleic acid
cells
composition according
molecule
differentiated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/022679 external-priority patent/WO2020190739A1/en
Publication of JP2022525193A publication Critical patent/JP2022525193A/ja
Publication of JP2022525193A5 publication Critical patent/JP2022525193A5/ja
Pending legal-status Critical Current

Links

JP2021555433A 2019-03-15 2020-03-13 Ｐｒｐｆ３１遺伝子発現ノックダウンによる、インビトロで分化したヒト細胞の生存の改善 Pending JP2022525193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818979P 2019-03-15 2019-03-15
US62/818,979 2019-03-15
PCT/US2020/022679 WO2020190739A1 (en) 2019-03-15 2020-03-13 Improved survival of human cells differentiated in vitro by prpf31 gene expression knockdown

Publications (2)

Publication Number Publication Date
JP2022525193A JP2022525193A (ja) 2022-05-11
JP2022525193A5 true JP2022525193A5 (enExample) 2023-03-17

Family

ID=72520464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555433A Pending JP2022525193A (ja) 2019-03-15 2020-03-13 Ｐｒｐｆ３１遺伝子発現ノックダウンによる、インビトロで分化したヒト細胞の生存の改善

Country Status (7)

Country Link
US (1) US20220152278A1 (enExample)
EP (1) EP3937956A4 (enExample)
JP (1) JP2022525193A (enExample)
CN (1) CN113710258A (enExample)
AU (1) AU2020241251A1 (enExample)
CA (1) CA3129782A1 (enExample)
WO (1) WO2020190739A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4356931A4 (en) * 2021-06-16 2025-07-16 Chigenovo Co Ltd VARIANT OF PRPF31 AND ITS USE
US20250082689A1 (en) * 2021-07-21 2025-03-13 University Of Washington Compositions and methods for enhancing cardiomyocyte transplant engraftment
JP2025534556A (ja) * 2022-10-21 2025-10-16 バイオジェン・エムエイ・インコーポレイテッド 網膜色素変性症を治療するための組成物及び方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US7875451B2 (en) * 2006-01-19 2011-01-25 The University Of Washington Formulation to improve survival of transplanted cells
AU2008204541B2 (en) * 2007-01-09 2014-07-10 Lead Pharma Cel Models Ip B.V. Provision of new cardiomyocyte progenitor cells and cardiomyocytes derived therefrom
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
AU2008346801A1 (en) * 2007-12-31 2009-07-16 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
EP2510087A2 (en) * 2009-12-11 2012-10-17 The Brigham and Women's Hospital, Inc. Pathogen restriction factors
EP4721752A2 (en) * 2011-12-30 2026-04-08 Cellscript, Llc Herstellung und verwendung von in vitro-synthetisierter ssrna zur einführung in säugetierzellen zur induktion einer biologischen oder biochemischen wirkung
PT3265568T (pt) * 2015-03-06 2020-08-20 Massachusetts Eye & Ear Infirmary Terapias de aumento de genes para a degeneração hereditária da retina causada por mutações no gene prpf31
FR3058160A1 (fr) * 2016-10-28 2018-05-04 Universite Pierre Et Marie Curie - Paris 6 (Upmc) Procede de differenciation de cellules souches pluripotentes en cardiomyocytes
JP7333271B2 (ja) * 2017-03-15 2023-08-24 ユニヴァーシティ オブ ワシントン 心筋細胞の成熟および生着を増強するための方法および組成物

Similar Documents

Publication Publication Date Title
KR100973615B1 (ko) 산후 포유류의 태반, 이의 용도 및 태반 줄기세포
Antonitsis et al. Cardiomyogenic potential of human adult bone marrow mesenchymal stem cells in vitro
JP2003527817A (ja) 遺伝子修飾したｃｄ３４−陰性付着成長性幹細胞および遺伝子療法におけるそれらの使用
US20060247195A1 (en) Method of altering cell properties by administering rna
JP2004344170A (ja) 心筋移植体およびそれに有用な細胞組成物
Huang et al. The migration and differentiation of hUC-MSCsCXCR4/GFP encapsulated in BDNF/chitosan scaffolds for brain tissue engineering
JP2019506895A (ja) 成人幹細胞から誘導されたペースメーカ細胞及びプルキンエ細胞
Yamada et al. Single-cell-derived mesenchymal stem cells overexpressing Csx/Nkx2. 5 and GATA4 undergo the stochastic cardiomyogenic fate and behave like transient amplifying cells
Han et al. Contribution of murine bone marrow mesenchymal stem cells to pancreas regeneration after partial pancreatectomy in mice
JP2010503727A (ja) 皮膚由来の幹細胞を含有する神経疾患治療用の細胞治療剤
CN110713984B (zh) 诱导人间充质干细胞生成功能内皮细胞的方法
KR20050037549A (ko) 인간 원종 줄기세포들을 자가 배양하기 위한 배지와 그의응용
CN107119020B (zh) 一种基于miR-9的肝损伤靶向间充质干细胞及其制备方法与应用
US10561688B2 (en) Method for preparing of endothelial cells by transformation (transdifferentiation) of adult fibroblast, and use thereof
CN117919400B (zh) iPS诱导定向分化的成内皮祖细胞和抗体联合治疗心脑血管疾病
JPWO2021020509A5 (enExample)
EP3479833B1 (en) Prophylactic or therapeutic agent for organ fibrosis
Xu et al. Therapeutic effects of CXCR4+ subpopulation of transgene‐free induced cardiosphere‐derived cells on experimental myocardial infarction
WO2019022780A1 (en) FUNCTIONAL PANCREATIC CELLS FROM FÉLINSPREADING ADIPOSE TISSUE
TWI852685B (zh) 由人類誘導多能幹細胞分化之心肌細胞、用以製備該心肌細胞的方法，以及其於治療心臟疾病的用途
CN112516146B (zh) Az191的药物新用途
US20050129666A1 (en) Compositions comprising preconditioned myoblasts having enhanced fusion properties
Kim et al. Generation of directly reprogrammed human endothelial cells derived from fibroblast using ultrasound
KR101521214B1 (ko) 다능성 세포의 제조방법
WO2024010872A1 (en) Systems and methods for growing mitochondria and coating thereof